Welcome to our dedicated page for Olink Holding AB (publ) American Depositary Shares news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding AB (publ) American Depositary Shares stock.
Olink Holding AB (publ) (Nasdaq: OLK) is a pioneering company in the field of proteomics, dedicated to accelerating scientific discoveries through its innovative Proximity Extension Assay (PEA) technology. Since its founding in 2016, Olink has been at the forefront of proteomics research, providing products and services designed to enhance the understanding of real-time human biology across multiple disease areas. The company’s platform is utilized by major biopharmaceutical firms, clinical institutions, and academic researchers globally.
Olink’s proprietary PEA technology is a versatile tool that enables researchers to conduct studies spanning from initial discovery to clinical trials and even diagnostic applications. This technology leverages existing lab infrastructure and installed instrumentation, making it a highly efficient and scalable solution.
Olink operates through two main segments: Kit and Services. In the Kit segment, the company provides reagents and consumables that researchers can use in their own laboratories. The Services segment offers access to Olink’s technology through its own labs, delivering high-quality data and insights to clients worldwide.
The company is headquartered in Uppsala, Sweden, and has a significant presence in Europe, North America, and Asia. Key revenue is generated from the United States, followed by Sweden, China, EMEA (excluding Sweden), Japan, and other regions. This geographical diversity emphasizes Olink’s global impact and reach.
Olink has recently garnered attention through several strategic initiatives and developments. Notably, on March 20, 2024, Thermo Fisher Scientific received clearance from the Swedish Inspectorate of Strategic Products for a proposed transaction with Olink, expected to be completed by mid-2024. This collaboration is anticipated to further strengthen Olink's capabilities and market presence.
Investor Contacts:
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
Email: jan.medina@olink.com
Media Contacts:
Michael B. Gonzales, PhD
VP Global Marketing
Mobile: +1 415 308 6467
Email: michael.gonzales@olink.com
Olink Holding AB (Nasdaq: OLK) announced a collaboration with Ultima Genomics to integrate the Olink® Explore assay with Ultima's sequencing technology, enhancing high-throughput proteomics applications. Initial proof of concept data indicates similar performance to existing assays, potentially expanding access to Olink's innovative technology. This partnership aims to provide clients with optimal sequencing platform options as demand for proteomics grows. Olink believes this collaboration will be crucial in developing the next-generation sequencing market.
Olink and Singular Genomics Systems have partnered to integrate Olink's Explore proteomics platform with Singular's G4 Sequencing Platform, utilizing Max Read kits to enable up to 4 billion reads per run. This collaboration aims to enhance throughput and reduce costs in proteomics research. The partnership reflects Olink's commitment to provide flexible solutions for its customers and extend the application portfolio for G4 users. Both companies emphasize the benefits of this integrated solution, designed to optimize sequencing choices for proteomics customers.
Olink Holding AB (Nasdaq: OLK) has collaborated with Element Biosciences to enhance the Olink® Explore high-throughput proteomics platform with the AVITI System, a next-generation sequencing platform launched in March 2022. A proof-of-concept study indicates high compatibility between the two technologies. This partnership aims to expand Olink's product accessibility and integrate advanced applications for researchers. CEO Jon Heimer emphasized the importance of making their products widely available to enhance biological understanding.
Olink Holding AB (Nasdaq: OLK) has partnered with Pharma Foods International (PFI) to utilize Olink's technology for protein analysis services in Japan. This collaboration marks PFI as the first firm in Japan to offer services using the Olink Signature Q100 platform, which will aid in their development of pharmaceuticals and functional foods. This partnership aligns with Olink's strategy to penetrate the food supplement market, leveraging PFI's 20 years of experience in the industry to meet market demands.
Olink Holding AB (Nasdaq: OLK) will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference on June 14, 2022, at 2:00 pm PT / 5:00 pm ET. Company management will take part in a fireside chat during the event. Interested parties can access a live and archived webcast of the discussion through the Investors section of Olink's website. Founded in 2016 and headquartered in Uppsala, Sweden, Olink is focused on accelerating proteomics to enhance patient outcomes through innovative scientific solutions.
Olink Holding AB (Nasdaq: OLK) reported Q1 2022 revenue of $22.7 million, a 66% increase from Q1 2021. Key drivers included a 74% growth in analysis services revenue, totaling $16.6 million. Adjusted EBITDA was ($9.1) million with a net loss of ($12.2) million, improving from a net loss of ($14.3) million in the prior year. The company maintains its 2022 revenue guidance of $138-$145 million, signaling expected growth of 45%-53%. Olink's investment in commercial and R&D initiatives is set to support continued growth.
Olink Holding AB (Nasdaq: OLK) announced its collaboration with Oxford Genomics at the University of Oxford, marking it as the first Olink certified laboratory in the UK. This partnership aims to leverage Olink's Explore platform to enhance disease research, particularly for complex conditions like Parkinson's and Alzheimer's. The advanced Olink Explore 3072 platform enables measurement of up to 3,000 proteins per sample, employing Proximity Extension Assay technology.
CEO Jon Heimer emphasized the significance of this partnership in advancing personalized medicine and accelerating drug development.
Olink Holding AB (Nasdaq: OLK) will release its first-quarter 2022 financial results on May 12, 2022, before the market opens. A conference call will follow at 8:00 am ET, where management will discuss the results. Interested investors can participate by dialing (833) 562-0120 for domestic calls or (661) 567-1096 for international calls, using Conference ID: 5650306. A live webcast will also be available on the Olink website, with an archived replay for at least 90 days.
At the Annual General Meeting (AGM) of Olink Holding AB on April 7, 2022, several key resolutions were adopted. The AGM approved the income statement and balance sheet for 2021, with no dividends declared for that financial year. The Board of Directors' composition was confirmed, including the re-election of Jon Hindar as Chair. Additionally, the AGM approved two Long Term Incentive programs, potentially diluting shares by 0.14% and 1.63%. Authorization was granted for the Board to issue new shares, limited to a dilution of 20%. The total remuneration for the Board amounted to USD 640,000.
Olink Holding AB (Nasdaq: OLK) has made its 2021 Annual Report available on its website, showcasing its commitment to advancing proteomics. The company collaborates with biopharmaceutical firms and academic institutions to enhance understanding of human biology, aiming for impactful healthcare solutions. Established in 2016, Olink operates globally, focusing on pivotal scientific discoveries across various disease areas. The report reflects Olink's dedication to both innovation and patient outcomes.
FAQ
What is the current stock price of Olink Holding AB (publ) American Depositary Shares (OLK)?
What is the market cap of Olink Holding AB (publ) American Depositary Shares (OLK)?
What does Olink Holding AB specialize in?
What are the main segments of Olink's operations?
Where is Olink Holding AB headquartered?
Which markets generate the most revenue for Olink?
What is Olink's Proximity Extension Assay (PEA) technology?
Who are the key contacts for investors and media at Olink?
What recent strategic developments has Olink been involved in?
When was Olink Holding AB founded?
What industries benefit from Olink's services?
How can researchers use Olink's products?
